Written Informed Consent Act
- Bill Number
- S. 3314
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Armed Forces and National Security
- Status
- Introduced
- Latest Action
- 2025-12-02: Read twice and referred to the Committee on Veterans' Affairs.
- Last Updated
- 2026-06-10T11:03:26Z
AI-Generated Summary
Purpose
The "Written Informed Consent Act" (S. 3314) aims to strengthen patient protections in the Department of Veterans Affairs (VA) by requiring written informed consent for a broader range of medications. Informed consent means patients must be fully informed about the risks, benefits, and alternatives of a treatment before agreeing to it. This bill expands an existing VA policy focused on opioids to include other commonly prescribed drugs that can have significant side effects.
Key Provisions
- Directs the Secretary of Veterans Affairs to revise VA Directive 1005 (issued May 13, 2020), which currently requires informed consent only for long-term opioid therapy used to treat pain.
- The updated directive must extend informed consent requirements to the following medication categories:
- Antipsychotics: Drugs used to manage symptoms of conditions like schizophrenia or bipolar disorder.
- Stimulants: Medications often prescribed for attention deficit hyperactivity disorder (ADHD) or narcolepsy.
- Antidepressants: Treatments for depression, anxiety, or other mood disorders.
- Anxiolytics: Drugs to reduce anxiety, such as benzodiazepines.
- Narcotics: Pain-relieving opioids, building on the existing policy.
Significant Changes to Existing Law
- The original directive applies solely to long-term opioid use for pain management. This bill broadens it to cover additional classes of medications, particularly psychotropic drugs (those affecting mental health) and narcotics.
- No new penalties or enforcement mechanisms are introduced; the change focuses on policy updates within the VA's internal guidelines.
Potential Impacts
- On government agencies: The VA will need to train staff, update forms and procedures, and monitor compliance, potentially increasing administrative workload but improving care standards.
- On citizens: Veterans receiving these medications will gain clearer information about potential risks (e.g., side effects like dependency or cognitive changes), empowering them to make better-informed decisions about their treatment.
- On international relations: No direct impact, as this is a domestic VA policy change.
Main Stakeholders Affected
- Veterans: Primary beneficiaries, as they receive VA healthcare and these medications.
- VA healthcare providers: Doctors, nurses, and pharmacists who prescribe and administer these drugs, now required to obtain written consent.
- VA leadership: The Secretary and Veterans Health Administration (VHA) staff responsible for implementing the directive update.
Notable Legal, Constitutional, or Political Implications
- Legal: Reinforces patient rights under federal healthcare laws by promoting transparency in treatment, aligning with broader medical ethics standards. It could reduce liability for the VA if adverse events occur, as consent documentation provides legal protection.
- Constitutional: No significant issues; it supports due process and individual autonomy without infringing on rights.
- Political: Highlights bipartisan interest in veteran mental health and pain management (introduced by Senators Sheehy and Tuberville). It may influence future VA reforms by addressing concerns over over-prescription of psychotropic drugs, potentially sparking debates on medication safety in federal healthcare.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (6)
Sen. Tuberville, Tommy [R-AL], Sen. Daines, Steve [R-MT], Sen. Blackburn, Marsha [R-TN], Sen. Risch, James E. [R-ID], Sen. Lee, Mike [R-UT], Sen. Justice, James C. [R-WV]
Recent Actions
- 2025-12-02: Read twice and referred to the Committee on Veterans' Affairs.
- 2025-12-02: Introduced in Senate
Bill Versions
- Written Informed Consent Act — issued 2025-12-02 — PDF (2 pages)